A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL) (RESPONSE)
A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
Sponsor: Nora Therapeutics, Inc.
Listed as NCT02156063, this PHASE2 trial focuses on Recurrent Miscarriage and Recurrent Pregnancy Loss and remains ongoing. Sponsored by Nora Therapeutics, Inc., it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nora Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ashington, United Kingdom , Birmingham, United Kingdom , Chertsey, Surrey, United Kingdom , Coventry, United Kingdom , Edinburgh, United Kingdom , Frimley, Surrey, United Kingdom , Leeds, United Kingdom , Liverpool, United Kingdom , London, United Kingdom , Manchester, United Kingdom and 9 more locations